Certara, a provider of model-informed drug development and decision support software, has announced the launch of BaseCase Data Manager, which allows clients to build interactive, data-driven mobile tools using real-world data sources, such as healthcare claims, costs, quality, outcomes, and population data.
Press Releases
Certara, a provider of global model-informed drug development software, has announced the launch of version 19.6 of D360, its scientific informatics platform for drug discovery and development. Designed to meet the scientific researcher’s need to quickly access, understand and share data, the D360 platform is delivered through its toolkits – small molecule discovery, biologics discovery, and pre-clinical translation – each tailored to meet specific research goals. This latest version of D360 takes its name from its release date; it is the 2019 mid-year release.
Integrated DNA Technologies (IDT) has launched a preferred sequencing provider program with McDonnell Genome Institute (MGI) at Washington University.
Qumulo, a provider of hybrid cloud file storage has announced that Elmec, an Italian managed services company specialising in IT solutions, has selected Qumulo’s file storage to serve the rapidly evolving needs of its enterprise clients.
Microway, a provider of computational clusters, servers, and workstations for AI and HPC applications, has announced that it is now shipping 2nd Generation Intel Xeon Scalable processors ('Cascade Lake-SP') across all Microway Xeon systems including next-generation NumberSmasher clusters, servers, and WhisperStations.
Verne Global, a provider of advanced data center solutions for high performance computing (HPC), has announced that it has joined the
The organisers of the Laboratory Informatics Forum have prepared a report which details challenges and new trends across the laboratory informatics industries
Certara, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that it has formed a new practice area called Certara Global Health (CGH) to focus its technological expertise on helping to achieve worldwide equity in health. CGH is a new product development innovation practice inspired by Certara’s drug development and scientific due diligence work for the Bill & Melinda Gates Foundation.
At the annual Fujitsu Innovation Gathering today in London, Fujitsu Laboratories of Europe today announces a new AI technology that enhances Electronic Health Record (EHR) management, automating the processing of unstructured (free text) medical notes and achieving time savings of more than 90 per cent with significantly improved accuracy.
Emerald Publishing has announced today that its new Insight digital research platform has gone live, following a significant investment in technology and many months of development in partnership with software development consultancy 67 Bricks
Pages
Latest issue
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
